scholarly journals Testosterone therapy decreases subcutaneous fat and adiponectin in aging men

2012 ◽  
Vol 166 (3) ◽  
pp. 469-476 ◽  
Author(s):  
L Frederiksen ◽  
K Højlund ◽  
D M Hougaard ◽  
T H Mosbech ◽  
R Larsen ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Fat Mass ◽  
Subcutaneous Fat ◽  
Fat Distribution ◽  
Controlled Study ◽  
Testosterone Therapy ◽  
Testosterone Levels ◽  
Bioavailable Testosterone ◽  
Aging Men ◽  
Total Fat

ObjectiveTestosterone therapy increases lean body mass and decreases total fat mass in aging men with low normal testosterone levels. The major challenge is, however, to determine whether the metabolic consequences of testosterone therapy are overall positive. We have previously reported that 6-month testosterone therapy did not improve insulin sensitivity. We investigated the effect of testosterone therapy on regional body fat distribution and on the levels of the insulin-sensitizing adipokine, adiponectin, in aging men with low normal bioavailable testosterone levels.DesignA randomized, double-blinded, placebo-controlled study on 6-month testosterone treatment (gel) in 38 men, aged 60–78 years, with bioavailable testosterone <7.3 nmol/l, and a waist circumference >94 cm.MethodsCentral fat mass (CFM) and lower extremity fat mass (LEFM) were measured by dual X-ray absorptiometry. Subcutaneous abdominal adipose tissue (SAT), visceral adipose tissue (VAT), and thigh subcutaneous fat area (TFA) were measured by magnetic resonance imaging. Adiponectin levels were measured using an in-house immunofluorometric assay. Coefficients (b) represent the placebo-controlled mean effect of intervention.ResultsLEFM was decreased (b=−0.47 kg, P=0.07) while CFM did not change significantly (b=−0.66 kg, P=0.10) during testosterone therapy. SAT (b=−3.0%, P=0.018) and TFA (b=−3.0%, P<0.001) decreased, while VAT (b=1.0%, P=0.54) remained unchanged. Adiponectin levels decreased during testosterone therapy (b=−1.3 mg/l, P=0.001).ConclusionTestosterone therapy decreased subcutaneous fat on the abdomen and lower extremities, but visceral fat was unchanged. Moreover, adiponectin levels were significantly decreased during testosterone therapy.

scholarly journals In Vivo Fat Quantification: Monitoring Effects of a 6-Week Non-Energy-Restricted Ketogenic Diet in Healthy Adults Using MRI, ADP and BIA

Nutrients ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 244
Author(s):  
Martin Buechert ◽  
Thomas Lange ◽  
Peter Deibert ◽  
Paul Urbain
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Ketogenic Diet ◽  
Fat Mass ◽  
Subcutaneous Fat ◽  
Fat Distribution ◽  
Abdominal Fat ◽  
Healthy Adults ◽  
Resonance Imaging ◽  
Total Fat

The ketogenic diet (KD) is a very low-carbohydrate, high-fat, and adequate-protein diet that induces many metabolic adaptations when calorie intake is not limited. Its therapeutic use in a range of diseases including cancer is currently being investigated. Our objective was to firstly assess the impact of a 6-week non-energy-restricted KD on the abdominal fat distribution and the hepatic fat composition in healthy adults. Body fat distribution and composition were measured by comparing magnetic resonance imaging (MRI) and spectroscopy (MRS) results with air displacement plethysmography (ADP) and bioelectrical impedance analysis (BIA) measurements. A total of 12 subjects from the KetoPerformance study were recruited for this ancillary study. Body mass index (BMI), total mass, total fat mass, total subcutaneous mass, and subcutaneous fat mass decreased significantly. None of the MRS parameters showed a significant change during the study. Even though the average change in body weight was >2kg, no significant changes in intrahepatic lipid (IHL) content could be observed. Total fat mass and total fat-free mass derived from MRI has a strong correlation with the corresponding values derived from BIA and ADP data. BMI and the absolute fat parameter of all three modalities decreased, but there were no or only minor changes regarding the fat-free parameter. Magnetic resonance imaging provides body composition information on abdominal fat distribution changes during a ketogenic diet. This information is complementary to anthropomorphic and laboratory measures and is more detailed than the information provided by ADP and BIA measures. It was shown that there was no significant change in internal fat distribution, but there was a decrease in subcutaneous fat.

scholarly journals Hypogonadism in the Aging Male Diagnosis, Potential Benefits, and Risks of Testosterone Replacement Therapy

2012 ◽  
Vol 2012 ◽  
pp. 1-20 ◽  
Author(s):  
Prasanth N. Surampudi ◽  
Christina Wang ◽  
Ronald Swerdloff
Keyword(s):  
Replacement Therapy ◽  
Serum Testosterone ◽  
Diagnostic Methods ◽  
Testosterone Replacement ◽  
Controlled Study ◽  
Testosterone Replacement Therapy ◽  
Testosterone Therapy ◽  
Testosterone Levels ◽  
Aging Men ◽  
Potential Benefits

Hypogonadism in older men is a syndrome characterized by low serum testosterone levels and clinical symptoms often seen in hypogonadal men of younger age. These symptoms include decreased libido, erectile dysfunction, decreased vitality, decreased muscle mass, increased adiposity, depressed mood, osteopenia, and osteoporosis. Hypogonadism is a common disorder in aging men with a significant percentage of men over 60 years of age having serum testosterone levels below the lower limits of young male adults. There are a variety of testosterone formulations available for treatment of hypogonadism. Data from many small studies indicate that testosterone therapy offers several potential benefits to older hypogonadal men. A large multicenter NIH supported double blind, placebo controlled study is ongoing, and this study should greatly enhance the information available on efficacy and side effects of treatment. While safety data is available across many age groups, there are still unresolved concerns associated with testosterone therapy. We have reviewed the diagnostic methods as well as benefits and risks of testosterone replacement therapy for hypogonadism in aging men.

Role of smoking on body fat distribution and coronary artery disease

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
M Sabet ◽  
S Elkaffas ◽  
S.W.G Bakhoum ◽  
H Kandil
Keyword(s):  
Computed Tomography ◽  
Coronary Artery Disease ◽  
Adipose Tissue ◽  
Coronary Artery ◽  
Body Fat ◽  
Fat Distribution ◽  
Relative Distribution ◽  
Coronary Artery Atherosclerosis ◽  
Total Fat ◽  
Artery Disease

Abstract Introduction Smoking and obesity are recognized as important modifiable risk factors for coronary artery disease (CAD). However, the general perception that smoking protects against obesity is a common reason for starting, and/or not quitting smoking. Purpose To detect the quantity, quality and relative distribution of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) estimated by abdominal computed tomography in smokers versus non- smokers. Methods The abdominal muscular wall was traced manually to calculate SAT and VAT areas (cm2) (outside and inside abdominal muscular wall respectively) as well as SAT density [Hounsfield units (HU)] at L4-L5 in 409 consecutive patients referred for evaluation of chest pain by multi-slice computed tomography coronary angiography (MSCT-CA). Results 26% of the studied patients (n=107) were current smokers, while the remaining 74% (n=302) never smoked. Coronary artery atherosclerosis was more prevalent in smokers compared to non-smokers (64.5% vs 55.0%; p=0.09). Smokers had statistically significantly lower body mass index (BMI) (31.2±4.3 vs. 32.5±4.7 kg/m2; p=0.015), hip circumference (HC) (98.6±22.5 vs. 103.9±20.9 cm; p=0.031), total fat area (441.62±166.34 vs. 517.95±169.51cm2; p&lt;0.001), and SAT area (313.07±125.54 vs. 390.93±143.28 cm2; p&lt;0.001) as compared to non-smokers. However, smokers had statistically significantly greater waist-to-hip ratio (0.98±0.08 vs. 0.96±0.08; p=0.010), VAT/SAT area ratio (0.41±0.23 vs. 0.35±0.20; p=0.013), and denser SAT depot (−98.91±7.71 vs. −102.08±6.44 HU; p&lt;0.001). Conclusion Smoking contributes to CAD and to the pathogenic redistribution of body fat towards VAT, through limiting SAT potential to expand. Funding Acknowledgement Type of funding source: None

scholarly journals Acute fat loss does not affect bone mass

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Marie K. Lagerquist ◽  
Karin L. Gustafsson ◽  
Petra Henning ◽  
Helen Farman ◽  
Jianyao Wu ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Bone Mass ◽  
Fat Mass ◽  
Tissue Loss ◽  
Obese Mice ◽  
Long Term Effects ◽  
High Bone Mass ◽  
Age Related ◽  
Total Fat ◽  
Old Mice

AbstractObesity has previously been thought to protect bone since high body weight and body mass index are associated with high bone mass. However, some more recent studies suggest that increased adiposity negatively impacts bone mass. Here, we aimed to test whether acute loss of adipose tissue, via adipocyte apoptosis, alters bone mass in age-related obese mice. Adipocyte apoptosis was induced in obese male FAT-ATTAC mice through AP20187 dimerizer-mediated activation of caspase 8 selectively in adipocytes. In a short-term experiment, dimerizer was administered to 5.5 month-old mice that were terminated 2 weeks later. At termination, the total fat mass weighed 58% less in dimerizer-treated mice compared with vehicle-treated controls, but bone mass did not differ. To allow for the detection of long-term effects, we used 9-month-old mice that were terminated six weeks after dimerizer administration. In this experiment, the total fat mass weighed less (− 68%) in the dimerizer-treated mice than in the controls, yet neither bone mass nor biomechanical properties differed between groups. Our findings show that adipose tissue loss, despite the reduced mechanical loading, does not affect bone in age-related obese mice. Future studies are needed to test whether adipose tissue loss is beneficial during more severe obesity.

Testosterone Therapy Decreased Adiponectin and Subcutaneous Fat in Aging Men

2011 ◽  
pp. P3-470-P3-470
Author(s):  
Louise Frederiksen ◽  
Kurt Hojlund ◽  
David M Hougaard ◽  
Thomas H Mosbech ◽  
Rasmus Larsen ◽  
...  
Keyword(s):  
Subcutaneous Fat ◽  
Testosterone Therapy ◽  
Aging Men

scholarly journals Volumes of coronary plaque disease in relation to body mass index, waist circumference, truncal fat mass and epicardial adipose tissue in patients with type 2 diabetes mellitus and controls

2019 ◽  
Vol 16 (4) ◽  
pp. 328-336 ◽  
Author(s):  
Søren Gullaksen ◽  
Kristian Løkke Funck ◽  
Esben Laugesen ◽  
Troels Krarup Hansen ◽  
Damini Dey ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Adipose Tissue ◽  
Waist Circumference ◽  
Body Mass ◽  
Fat Mass ◽  
Epicardial Adipose Tissue ◽  
Fat Distribution ◽  
Coronary Plaque ◽  
Calcified Plaque ◽  
Regional Fat Distribution

Objectives: Coronary atherosclerosis in patients with type 2 diabetes mellitus may be promoted by regional fat distribution. We investigated the association between anthropometric measures of obesity, truncal fat mass, epicardial adipose tissue and coronary atherosclerosis in asymptomatic patients and matched controls. Methods: We examined 44 patients and 59 controls [mean (standard deviation) age 64.4 ± 9.9 vs 61.8 ± 9.7, male 50% vs 47%, diabetes duration mean (standard deviation) 7.7 ± 1.5] with coronary computed tomography angiography. Coronary plaques were quantified as total, calcified, non-calcified and low-density non-calcified plaque volumes (mm3). Regional fat distribution was assessed by dual-energy X-ray absorptiometry, body mass index (kg/m2), waist circumference (cm) and epicardial fat volume (mm3). Endothelial function and systemic inflammation were evaluated by peripheral arterial tonometry (log transformed Reactive Hyperemia Index) and C-reactive protein (mg/L). Results: Body mass index and waist circumference ( p < 0.02) were associated with coronary plaque volumes. Body mass index was associated with low-density non-calcified plaque volume after adjustment for age, sex and diabetes status ( p < 0.01). Truncal fat mass ( p > 0.51), waist circumference ( p > 0.06) and epicardial adipose tissue ( p > 0.17) were not associated with coronary plaque volumes in adjusted analyses. Conclusion: Body mass index is associated with coronary plaque volumes in diabetic as well as non-diabetic individuals.

scholarly journals Changes in Body Fat Distribution in Antiretroviral-Naive HIV-Positive Individuals Initiating Current ART Regimens

2018 ◽  
Vol 104 (3) ◽  
pp. 900-905 ◽  
Author(s):  
Juan Tiraboschi ◽  
Antonio Navarro-Alcaraz ◽  
Dolors Giralt ◽  
Carmen Gomez-Vaquero ◽  
Maria Saumoy ◽  
...  
Keyword(s):  
Body Mass ◽  
Body Fat ◽  
Fat Mass ◽  
Fat Distribution ◽  
Body Fat Distribution ◽  
The Body ◽  
Strand Transfer ◽  
Mass Ratio ◽  
Total Fat ◽  
Fat Mass Ratio

Abstract Objectives To describe the changes in body fat distribution (BFD) occurring over 60 months in a group of antiretroviral therapy (ART)-naive individuals starting different antiretroviral regimens. Methods A prospective ongoing fat change assessment including clinical evaluation and dual X-ray absorptiometry scan is being conducted in all consecutive patients initiating ART from January 2008. Arm, leg, trunk, and total fat as well as fat mass ratio were determined. Results A total of 146 patients were included (80% male, 40% MSM). Mean age was 44 years, HIV-1 RNA was 4.98 log10 copies/mL, and CD4 count was 254 cells/μL. The most common initial antiretroviral combination included non-nucleoside reverse transcription inhibitor (NNRTI) drugs followed by protease inhibitor (PI) and integrase strand transfer inhibitor (INSTI)-based regimens. At month 36, an increase was seen in the body mass index (BMI), total fat, trunk fat, and limb fat. The fat mass ratio (FMR) also showed a significant increase in both men and women (P = 0.001). In patients receiving NNRTI- or INSTI-based regimens (but not PIs), there was a marginal but statistically significant increase in the FMR (0.10 and 0.07, respectively; P = 0.01). Sixty-two subjects completed 60 months of follow-up. FMR showed a significant increase even in the PI group at this time point (P &lt; 0.03). Conclusions We observed a significant increase in the fat and lean body mass in all compartments and treatment groups over 36 and 60 months. Clinically irrelevant differences were found in fat distribution regardless of the treatment group and baseline characteristics. The data suggest that current antiretroviral regimens have little impact on BFD during the first years of treatment.

scholarly journals Effect of testosterone on markers of mitochondrial oxidative phosphorylation and lipid metabolism in muscle of aging men with subnormal bioavailable testosterone

2014 ◽  
Vol 171 (1) ◽  
pp. 77-88 ◽  
Author(s):  
Stine J Petersson ◽  
Louise L Christensen ◽  
Jonas M Kristensen ◽  
Rikke Kruse ◽  
Marianne Andersen ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Lipid Metabolism ◽  
Insulin Sensitivity ◽  
Lipid Oxidation ◽  
Mitochondrial Biogenesis ◽  
Protein Abundance ◽  
Mrna Levels ◽  
Testosterone Therapy ◽  
Bioavailable Testosterone ◽  
Aging Men

ObjectiveRecent studies have indicated that serum testosterone in aging men is associated with insulin sensitivity and expression of genes involved in oxidative phosphorylation (OxPhos), and that testosterone treatment increases lipid oxidation. Herein, we investigated the effect of testosterone therapy on regulators of mitochondrial biogenesis and markers of OxPhos and lipid metabolism in the skeletal muscle of aging men with subnormal bioavailable testosterone levels.MethodsSkeletal muscle biopsies were obtained before and after treatment with either testosterone gel (n=12) or placebo (n=13) for 6 months. Insulin sensitivity and substrate oxidation were assessed by euglycemic–hyperinsulinemic clamp and indirect calorimetry. Muscle mRNA levels and protein abundance and phosphorylation of enzymes involved in mitochondrial biogenesis, OxPhos, and lipid metabolism were examined by quantitative real-time PCR and western blotting.ResultsDespite an increase in lipid oxidation (P<0.05), testosterone therapy had no effect on insulin sensitivity or mRNA levels of genes involved in mitochondrial biogenesis (PPARGC1A,PRKAA2, andPRKAG3), OxPhos (NDUFS1,ETFA,SDHA,UQCRC1, andCOX5B), or lipid metabolism (ACADVL,CD36,CPT1B,HADH, andPDK4). Consistently, protein abundance of OxPhos subunits encoded by both nuclear (SDHAandUQCRC1) and mitochondrial DNA (ND6) and protein abundance and phosphorylation of AMP-activated protein kinase and p38 MAPK were unaffected by testosterone therapy.ConclusionThe beneficial effect of testosterone treatment on lipid oxidation is not explained by increased abundance or phosphorylation-dependent activity of enzymes known to regulate mitochondrial biogenesis or markers of OxPhos and lipid metabolism in the skeletal muscle of aging men with subnormal bioavailable testosterone levels.

scholarly journals Circulating steroid levels as correlates of adipose tissue phenotype in premenopausal women

2018 ◽  
Vol 0 (0) ◽  
Author(s):  
Geneviève B. Marchand ◽  
Anne-Marie Carreau ◽  
Sofia Laforest ◽  
Julie-Anne Côté ◽  
Marleen Daris ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Plasma Levels ◽  
Subcutaneous Fat ◽  
Premenopausal Women ◽  
Fat Distribution ◽  
Adipocyte Size ◽  
Fat Percentage ◽  
Potential Marker ◽  
Liquid Chromatography Tandem Mass ◽  
Adipocyte Hypertrophy

AbstractBackgroundObesity-related alterations in the circulating steroid hormone profile remain equivocal in women. Our objective was to identify circulating steroid levels that relate to increased adiposity and altered adipose phenotype in premenopausal women.Materials and methodsIn a sample of 42 premenopausal women [age 46 ± 3 years; body mass index (BMI) 27.1 ± 4.2 kg/m2], 19 plasma steroids were quantified by electrospray ionization-liquid chromatography-tandem mass spectroscopy (ESI-LC-MS/MS). Body composition and fat distribution were assessed by dual-energy X-ray absorptiometry (DXA) and computed tomography (CT), respectively. Markers of adipose tissue function including adipocyte size distributions, radiological attenuation and macrophage infiltration were also analyzed in surgically obtained visceral and subcutaneous fat samples.ResultsMany negative correlations were observed between adiposity measurements such as BMI, body fat percentage or total abdominal adipose tissue area and plasma levels of androstenedione (Δ4) (r = −0.33 to −0.39, p ≤ 0.04), androsterone (ADT) (r = −0.30 to −0.38, p ≤ 0.05) and steroid precursor pregnenolone (PREG) (r = −0.36 to −0.46, p ≤ 0.02). Visceral adipocyte hypertrophy was observed in patients with low PREG concentrations (p < 0.05). Visceral adipose tissue radiologic attenuation, a potential marker of adipocyte size, was also positively correlated with PREG levels (r = 0.33, p < 0.05). Low levels of PREG were related to increased number of macrophages infiltrating visceral and subcutaneous adipose tissue (p < 0.05).ConclusionPlasma levels of androgens and their precursors are lower in women with increased adiposity and visceral adipocyte hypertrophy. Low circulating PREG concentration may represent a marker of adipose tissue dysfunction.

scholarly journals Association between Interleukin-15 and Obesity: Interleukin-15 as a Potential Regulator of Fat Mass

2008 ◽  
Vol 93 (11) ◽  
pp. 4486-4493 ◽  
Author(s):  
Anders Rinnov Nielsen ◽  
Pernille Hojman ◽  
Christian Erikstrup ◽  
Christian Philip Fischer ◽  
Peter Plomgaard ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Skeletal Muscle ◽  
Adipose Tissue ◽  
Fat Mass ◽  
Negative Association ◽  
Tissue Mass ◽  
Adipose Tissue Mass ◽  
Interleukin 15 ◽  
Total Fat

Objective: IL-15 decreases lipid deposition in preadipocytes and decreases the mass of white adipose tissue in rats, indicating that IL-15 may take part in regulating this tissue. IL-15 is expressed in human skeletal muscle and skeletal muscle may be a source of plasma IL-15 and in this way regulate adipose tissue mass. Design: The relation between skeletal muscle IL-15 mRNA expression, plasma IL-15, and adipose tissue mass was studied in 199 humans divided into four groups on the basis of obesity and type 2 diabetes. Furthermore, using a DNA electrotransfer model, we assessed the effect of IL-15 overexpression in skeletal muscle of mice. Results: In humans, multiple regression analysis showed a negative association between plasma IL-15 and total fat mass (P &lt; 0.05), trunk fat mass (P &lt; 0.01), and percent fat mass (P &lt; 0.05), independent of type 2 diabetes. Negative associations were also found between muscle IL-15 mRNA and obesity parameters. IL-15 overexpression in skeletal muscle of mice reduced trunk fat mass but not sc fat mass. Conclusions: Our results indicate that IL-15 may be a regulator of trunk fat mass.

Sign in / Sign up

Export Citation Format

Share Document